Login
Evidence Feed
About
Conferences
New
Diagnostics
New
Top genes
New
Contact us
^
Login
CANCER:
Chronic Lymphocytic Leukemia
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
‹
Leukemia (1822
)
Acute Myelogenous Leukemia (825
)
Acute Lymphocytic Leukemia (378
)
Chronic Myeloid Leukemia (261
)
B Acute Lymphoblastic Leukemia (157
)
T Acute Lymphoblastic Leukemia (38
)
Childhood B Acute Lymphoblastic Leukemia (37
)
Hairy Cell Leukemia (18
)
Chronic Myelomonocytic Leukemia (16
)
Prolymphocytic Leukemia (14
)
Acute Promyelocytic Leukemia (12
)
Chronic Eosinophilic Leukemia (4
)
Juvenile Myelomonocytic Leukemia (4
)
Chronic Neutrophilic Leukemia (3
)
Leukemia (1822
)
Acute Myelogenous Leukemia (825
)
Acute Lymphocytic Leukemia (378
)
Chronic Myeloid Leukemia (261
)
B Acute Lymphoblastic Leukemia (157
)
T Acute Lymphoblastic Leukemia (38
)
Childhood B Acute Lymphoblastic Leukemia (37
)
Hairy Cell Leukemia (18
)
Chronic Myelomonocytic Leukemia (16
)
Prolymphocytic Leukemia (14
)
Acute Promyelocytic Leukemia (12
)
Chronic Eosinophilic Leukemia (4
)
Juvenile Myelomonocytic Leukemia (4
)
Chronic Neutrophilic Leukemia (3
)
›
Associations
(279)
Heatmap
News
Twitter
Trials
Reset Filters
Veri cancer hierarchy
x
x
x
x
Chr del(17p)
Chronic Lymphocytic Leukemia
Chr del(17p)
Chronic Lymphocytic Leukemia
zanubrutinib
Sensitive: A2 - Guideline
SOHO 2022 - 6 days (New B)
zanubrutinib
Sensitive
:
A2
SOHO 2022 - 6d
zanubrutinib
Sensitive: A2 - Guideline
SOHO 2022 - 6 days
zanubrutinib
Sensitive
:
A2
SOHO 2022 - 6 days - (New B)
Chr del(11q)
Chronic Lymphocytic Leukemia
Chr del(11q)
Chronic Lymphocytic Leukemia
zanubrutinib
Sensitive: B - Late Trials
SOHO 2022 - 6 days (New B)
zanubrutinib
Sensitive
:
B
SOHO 2022 - 6d
zanubrutinib
Sensitive: B - Late Trials
SOHO 2022 - 6 days
zanubrutinib
Sensitive
:
B
SOHO 2022 - 6 days - (New B)
CD20 positive
Chronic Lymphocytic Leukemia
CD20 positive
Chronic Lymphocytic Leukemia
rituximab-abbs
Sensitive: A1 - Approval
rituximab-abbs
Sensitive
:
A1
rituximab-abbs
Sensitive: A1 - Approval
rituximab-abbs
Sensitive
:
A1
No biomarker
Chronic Lymphocytic Leukemia
No biomarker
Chronic Lymphocytic Leukemia
rituximab + ibrutinib
Sensitive: A1 - Approval
rituximab + ibrutinib
Sensitive
:
A1
rituximab + ibrutinib
Sensitive: A1 - Approval
rituximab + ibrutinib
Sensitive
:
A1
Chr del(17p)
Chronic Lymphocytic Leukemia
Chr del(17p)
Chronic Lymphocytic Leukemia
venetoclax + obinutuzumab
Sensitive: A1 - Approval
venetoclax + obinutuzumab
Sensitive
:
A1
venetoclax + obinutuzumab
Sensitive: A1 - Approval
venetoclax + obinutuzumab
Sensitive
:
A1
TP53 mutation
Chronic Lymphocytic Leukemia
TP53 mutation
Chronic Lymphocytic Leukemia
venetoclax + obinutuzumab
Sensitive: A1 - Approval
venetoclax + obinutuzumab
Sensitive
:
A1
venetoclax + obinutuzumab
Sensitive: A1 - Approval
venetoclax + obinutuzumab
Sensitive
:
A1
No biomarker
Chronic Lymphocytic Leukemia
No biomarker
Chronic Lymphocytic Leukemia
venetoclax + obinutuzumab
Sensitive: A1 - Approval
venetoclax + obinutuzumab
Sensitive
:
A1
venetoclax + obinutuzumab
Sensitive: A1 - Approval
venetoclax + obinutuzumab
Sensitive
:
A1
No biomarker
Chronic Lymphocytic Leukemia
No biomarker
Chronic Lymphocytic Leukemia
orelabrutinib
Sensitive: A1 - Approval
orelabrutinib
Sensitive
:
A1
orelabrutinib
Sensitive: A1 - Approval
orelabrutinib
Sensitive
:
A1
CD20 expression
Chronic Lymphocytic Leukemia
CD20 expression
Chronic Lymphocytic Leukemia
rituximab-arrx
Sensitive: A1 - Approval
rituximab-arrx
Sensitive
:
A1
rituximab-arrx
Sensitive: A1 - Approval
rituximab-arrx
Sensitive
:
A1
TP53 mutation
Chronic Lymphocytic Leukemia
TP53 mutation
Chronic Lymphocytic Leukemia
venetoclax
Sensitive: A1 - Approval
venetoclax
Sensitive
:
A1
venetoclax
Sensitive: A1 - Approval
venetoclax
Sensitive
:
A1
No biomarker
Chronic Lymphocytic Leukemia
No biomarker
Chronic Lymphocytic Leukemia
rituximab-abbs
Sensitive: A1 - Approval
rituximab-abbs
Sensitive
:
A1
rituximab-abbs
Sensitive: A1 - Approval
rituximab-abbs
Sensitive
:
A1
No biomarker
Chronic Lymphocytic Leukemia
No biomarker
Chronic Lymphocytic Leukemia
Rixathon (rituximab biosimilar)
Sensitive: A1 - Approval
Rixathon (rituximab biosimilar)
Sensitive
:
A1
Rixathon (rituximab biosimilar)
Sensitive: A1 - Approval
Rixathon (rituximab biosimilar)
Sensitive
:
A1
No biomarker
Chronic Lymphocytic Leukemia
No biomarker
Chronic Lymphocytic Leukemia
rituximab-pvvr
Sensitive: A1 - Approval
rituximab-pvvr
Sensitive
:
A1
rituximab-pvvr
Sensitive: A1 - Approval
rituximab-pvvr
Sensitive
:
A1
No biomarker
Chronic Lymphocytic Leukemia
No biomarker
Chronic Lymphocytic Leukemia
venetoclax + rituximab
Sensitive: A1 - Approval
venetoclax + rituximab
Sensitive
:
A1
venetoclax + rituximab
Sensitive: A1 - Approval
venetoclax + rituximab
Sensitive
:
A1
Chr del(17p)
Chronic Lymphocytic Leukemia
Chr del(17p)
Chronic Lymphocytic Leukemia
venetoclax
Sensitive: A1 - Approval
venetoclax
Sensitive
:
A1
venetoclax
Sensitive: A1 - Approval
venetoclax
Sensitive
:
A1
No biomarker
Chronic Lymphocytic Leukemia
No biomarker
Chronic Lymphocytic Leukemia
zanubrutinib
Sensitive: A1 - Approval
zanubrutinib
Sensitive
:
A1
zanubrutinib
Sensitive: A1 - Approval
zanubrutinib
Sensitive
:
A1
No biomarker
Chronic Lymphocytic Leukemia
No biomarker
Chronic Lymphocytic Leukemia
ibrutinib
Sensitive: A1 - Approval
ibrutinib
Sensitive
:
A1
ibrutinib
Sensitive: A1 - Approval
ibrutinib
Sensitive
:
A1
No biomarker
Chronic Lymphocytic Leukemia
No biomarker
Chronic Lymphocytic Leukemia
ibrutinib + obinutuzumab
Sensitive: A1 - Approval
ibrutinib + obinutuzumab
Sensitive
:
A1
ibrutinib + obinutuzumab
Sensitive: A1 - Approval
ibrutinib + obinutuzumab
Sensitive
:
A1
No biomarker
Chronic Lymphocytic Leukemia
No biomarker
Chronic Lymphocytic Leukemia
obinutuzumab
Sensitive: A1 - Approval
obinutuzumab
Sensitive
:
A1
obinutuzumab
Sensitive: A1 - Approval
obinutuzumab
Sensitive
:
A1
No biomarker
Chronic Lymphocytic Leukemia
No biomarker
Chronic Lymphocytic Leukemia
rituximab
Sensitive: A1 - Approval
rituximab
Sensitive
:
A1
rituximab
Sensitive: A1 - Approval
rituximab
Sensitive
:
A1
No biomarker
Chronic Lymphocytic Leukemia
No biomarker
Chronic Lymphocytic Leukemia
ofatumumab
Sensitive: A1 - Approval
ofatumumab
Sensitive
:
A1
ofatumumab
Sensitive: A1 - Approval
ofatumumab
Sensitive
:
A1
CD20 positive
Chronic Lymphocytic Leukemia
CD20 positive
Chronic Lymphocytic Leukemia
rituximab
Sensitive: A1 - Approval
rituximab
Sensitive
:
A1
rituximab
Sensitive: A1 - Approval
rituximab
Sensitive
:
A1
No biomarker
Chronic Lymphocytic Leukemia
No biomarker
Chronic Lymphocytic Leukemia
venetoclax
Sensitive: A1 - Approval
venetoclax
Sensitive
:
A1
venetoclax
Sensitive: A1 - Approval
venetoclax
Sensitive
:
A1
No biomarker
Chronic Lymphocytic Leukemia
No biomarker
Chronic Lymphocytic Leukemia
rituximab/hyaluronidase
Sensitive: A1 - Approval
rituximab / hyaluronidase
Sensitive
:
A1
rituximab/hyaluronidase
Sensitive: A1 - Approval
rituximab / hyaluronidase
Sensitive
:
A1
Chr del(17p)
Chronic Lymphocytic Leukemia
Chr del(17p)
Chronic Lymphocytic Leukemia
ibrutinib
Sensitive: A1 - Approval
ibrutinib
Sensitive
:
A1
ibrutinib
Sensitive: A1 - Approval
ibrutinib
Sensitive
:
A1
No biomarker
Chronic Lymphocytic Leukemia
No biomarker
Chronic Lymphocytic Leukemia
obinutuzumab + acalabrutinib
Sensitive: A1 - Approval
obinutuzumab + acalabrutinib
Sensitive
:
A1
obinutuzumab + acalabrutinib
Sensitive: A1 - Approval
obinutuzumab + acalabrutinib
Sensitive
:
A1
No biomarker
Chronic Lymphocytic Leukemia
No biomarker
Chronic Lymphocytic Leukemia
obinutuzumab
Sensitive: A1 - Approval
obinutuzumab
Sensitive
:
A1
obinutuzumab
Sensitive: A1 - Approval
obinutuzumab
Sensitive
:
A1
No biomarker
Chronic Lymphocytic Leukemia
No biomarker
Chronic Lymphocytic Leukemia
acalabrutinib
Sensitive: A1 - Approval
acalabrutinib
Sensitive
:
A1
acalabrutinib
Sensitive: A1 - Approval
acalabrutinib
Sensitive
:
A1
Chr del(17p)
Chronic Lymphocytic Leukemia
Chr del(17p)
Chronic Lymphocytic Leukemia
rituximab + idelalisib
Sensitive: A1 - Approval
rituximab + idelalisib
Sensitive
:
A1
rituximab + idelalisib
Sensitive: A1 - Approval
rituximab + idelalisib
Sensitive
:
A1
TP53 mutation
Chronic Lymphocytic Leukemia
TP53 mutation
Chronic Lymphocytic Leukemia
rituximab + idelalisib
Sensitive: A1 - Approval
rituximab + idelalisib
Sensitive
:
A1
rituximab + idelalisib
Sensitive: A1 - Approval
rituximab + idelalisib
Sensitive
:
A1
Chr del(17p)
Chronic Lymphocytic Leukemia
Chr del(17p)
Chronic Lymphocytic Leukemia
acalabrutinib
Sensitive: A1 - Approval
acalabrutinib
Sensitive
:
A1
acalabrutinib
Sensitive: A1 - Approval
acalabrutinib
Sensitive
:
A1
TP53 mutation
Chronic Lymphocytic Leukemia
TP53 mutation
Chronic Lymphocytic Leukemia
acalabrutinib
Sensitive: A1 - Approval
acalabrutinib
Sensitive
:
A1
acalabrutinib
Sensitive: A1 - Approval
acalabrutinib
Sensitive
:
A1
No biomarker
Chronic Lymphocytic Leukemia
No biomarker
Chronic Lymphocytic Leukemia
alemtuzumab
Sensitive: A1 - Approval
alemtuzumab
Sensitive
:
A1
alemtuzumab
Sensitive: A1 - Approval
alemtuzumab
Sensitive
:
A1
TP53 mutation
Chronic Lymphocytic Leukemia
TP53 mutation
Chronic Lymphocytic Leukemia
idelalisib + ofatumumab
Sensitive: A1 - Approval
idelalisib + ofatumumab
Sensitive
:
A1
idelalisib + ofatumumab
Sensitive: A1 - Approval
idelalisib + ofatumumab
Sensitive
:
A1
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
